Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Hepatitis B Vaccine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Low dose |
| 2 | EXPERIMENTAL | Middle dose |
| 3 | EXPERIMENTAL | High dose |
| 4 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| 1018 ISS immunostimulatory oligonucleotide with HBV surface antigen | BIOLOGICAL | Intramuscular (IM) injections on Day 0, Week 4 and Week 24, plus a placebo (salt solution) injection at Week 8 |
| Hepatitis B Vaccine (Recombinant) | BIOLOGICAL | IM (in the muscle) injections on Day 0, Week 4, Week 8 and Week 24 |
Inclusion Criteria: * Willing and able to give written informed consent * Progressive loss of kidney function with more advanced stage 3 (GFR at least 45 mL/min) or stage 4 chronic kidney disease by National Kidney Foundation classification, and are expected to eventually go on hemodialysis * Body ...
Hepatitis B Vaccine is used for Hepatitis B, an infectious disease of the liver. It is being developed as a preventive vaccine for this condition. The vaccine is currently in clinical development and is not yet approved for use.
Dynavax Technologies Corporation (NASDAQ: DVAX) is developing Hepatitis B Vaccine. The company is conducting clinical trials to evaluate the safety and efficacy of this vaccine for Hepatitis B.
Hepatitis B Vaccine is in Phase 1 clinical development. It is an investigational vaccine and has not been approved by regulatory authorities. A Phase 1 trial has been completed to assess its safety.
Hepatitis B Vaccine has one completed Phase 1 trial, NCT00426712, titled 'Safety of HEPLISAV™ Hepatitis B Virus Vaccine in End-stage Kidney Failure Patients'. This trial enrolled 42 participants in the United States and was active-controlled.
Yes, Hepatitis B Vaccine is also known as HEPLISAV. The clinical trial NCT00426712 refers to the vaccine as HEPLISAV™, indicating that these names refer to the same investigational vaccine for Hepatitis B.